Reviva Pharmaceuticals Holdings, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | $-19.9M | $-29.9M | $-39.3M | $-28.3M | $-8.5M | $-3.8M | $-846.8K |
| Depreciation & Amortization | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | $0 | $591 | $645 |
| Amortization | — | — | — | — | — | — | — |
| Stock-Based Compensation | $2.2M | $1.6M | $3.4M | $176.7K | $106.7K | $0 | — |
| Net Cash from Operating Activities | $-24.6M | $-33.5M | $-28.3M | $-19.0M | $-10.7M | $-4.1M | $-218.4K |
| Investing Activities | |||||||
| Capital Expenditures | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | $5.7M | $-64.5M |
| Financing Activities | |||||||
| Dividends Paid | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $25.6M | $23.7M | $33.2M | $7.8M | $31.6M | $12.8M | $100.0K |
| Net Change in Cash | — | — | — | — | — | $-243.8K | $313.0K |
| Free Cash Flow | — | — | — | — | — | — | — |